New Triple-Drug attack on aggressive blood cancer
NCT ID NCT07257510
Summary
This study is testing a combination of three drugs (pomalidomide, orelabrutinib, and zuberitamab) in people newly diagnosed with mantle cell lymphoma, a type of blood cancer. The main goal is to see how well this combination clears the body of tiny amounts of leftover cancer cells after initial treatment. Patients who respond well will continue on two of the drugs for up to 18 cycles, while the study tracks survival and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA (MCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.